DE69942727D1 - Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie - Google Patents
Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen LeukemieInfo
- Publication number
- DE69942727D1 DE69942727D1 DE69942727T DE69942727T DE69942727D1 DE 69942727 D1 DE69942727 D1 DE 69942727D1 DE 69942727 T DE69942727 T DE 69942727T DE 69942727 T DE69942727 T DE 69942727T DE 69942727 D1 DE69942727 D1 DE 69942727D1
- Authority
- DE
- Germany
- Prior art keywords
- antibody
- chronic lymphocytic
- lymphocytic leukemia
- chimeric anti
- rituxan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C2/00—Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shape; Apparatus therefor
- C23C2/04—Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shape; Apparatus therefor characterised by the coating material
- C23C2/06—Zinc or cadmium or alloys based thereon
-
- C—CHEMISTRY; METALLURGY
- C23—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; CHEMICAL SURFACE TREATMENT; DIFFUSION TREATMENT OF METALLIC MATERIAL; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL; INHIBITING CORROSION OF METALLIC MATERIAL OR INCRUSTATION IN GENERAL
- C23C—COATING METALLIC MATERIAL; COATING MATERIAL WITH METALLIC MATERIAL; SURFACE TREATMENT OF METALLIC MATERIAL BY DIFFUSION INTO THE SURFACE, BY CHEMICAL CONVERSION OR SUBSTITUTION; COATING BY VACUUM EVAPORATION, BY SPUTTERING, BY ION IMPLANTATION OR BY CHEMICAL VAPOUR DEPOSITION, IN GENERAL
- C23C2/00—Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shape; Apparatus therefor
- C23C2/30—Fluxes or coverings on molten baths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10765898P | 1998-11-09 | 1998-11-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69942727D1 true DE69942727D1 (de) | 2010-10-14 |
Family
ID=22317751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69942727T Expired - Lifetime DE69942727D1 (de) | 1998-11-09 | 1999-11-09 | Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie |
Country Status (19)
Country | Link |
---|---|
US (2) | US7682612B1 (de) |
EP (7) | EP1949910A1 (de) |
JP (2) | JP4842435B2 (de) |
KR (2) | KR20010103655A (de) |
CN (2) | CN1679934B (de) |
AT (1) | ATE479443T1 (de) |
AU (1) | AU761844C (de) |
BR (1) | BR9915164A (de) |
CA (1) | CA2350058C (de) |
CY (2) | CY1111173T1 (de) |
DE (1) | DE69942727D1 (de) |
DK (2) | DK1616572T3 (de) |
ES (2) | ES2351149T3 (de) |
HK (1) | HK1047043A1 (de) |
MX (1) | MXPA01004648A (de) |
PT (2) | PT1616572E (de) |
TR (1) | TR200101299T2 (de) |
WO (1) | WO2000027428A1 (de) |
ZA (1) | ZA200103720B (de) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
IL141349A0 (en) | 1998-08-11 | 2002-03-10 | Idec Pharma Corp | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body |
EP1949910A1 (de) | 1998-11-09 | 2008-07-30 | Biogen Idec, Inc. | Behandlung von CLL unter Verwendung chimärer Anti-CD20-Antikörper |
IL146005A0 (en) | 1999-05-07 | 2002-07-25 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
JP2003535907A (ja) * | 2000-06-22 | 2003-12-02 | ユニバーシティ オブ アイオワ リサーチ ファウンデーション | 抗体誘導性細胞溶解を促進し、そして癌を処置するための方法 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US20020159996A1 (en) * | 2001-01-31 | 2002-10-31 | Kandasamy Hariharan | Use of CD23 antagonists for the treatment of neoplastic disorders |
WO2002102312A2 (en) * | 2001-06-14 | 2002-12-27 | Intermune, Inc. | Combination therapy of gamma-interferon and b cell specific antibodies |
US20090143328A1 (en) * | 2001-08-13 | 2009-06-04 | Mcdonald George | Method of Treating Cancer by Administration of Topical Active Corticosteroids |
US7329502B2 (en) | 2002-04-25 | 2008-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | ZAP-70 expression as a marker for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
UA99933C2 (ru) | 2003-04-09 | 2012-10-25 | Дженентек, Инк. | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
CA2897608C (en) | 2003-05-09 | 2018-07-31 | Duke University | Cd20-specific antibodies and methods employing same |
CA2526402A1 (en) | 2003-06-05 | 2005-01-20 | Genentech, Inc. | Blys antagonists and uses thereof |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
BRPI0510915A (pt) | 2004-06-04 | 2007-11-13 | Genentech Inc | método para o tratamento da esclerose múltipla e artigo manufaturado |
EP2213683B1 (de) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Varianten der Fc Regionen |
KR20080046135A (ko) | 2005-05-20 | 2008-05-26 | 제넨테크, 인크. | 자가면역 질환 대상체로부터의 생물학적 샘플의 예비처리 |
AU2006272597A1 (en) | 2005-07-25 | 2007-02-01 | Emergent Product Development Seattle Llc | Single dose use of CD20-specific binding molecules |
PL1912675T3 (pl) | 2005-07-25 | 2014-10-31 | Emergent Product Dev Seattle | Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20 |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
MX363905B (es) | 2006-06-12 | 2019-04-08 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
WO2008034071A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Method of identifying patients suitable for high-dose cyclophosphamide treatment |
WO2008034076A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclophosphamide in combination with immune therapeutics |
WO2008034074A2 (en) | 2006-09-15 | 2008-03-20 | The Johns Hopkins University | Cyclosphosphamide in combination with anti-idiotypic vaccines |
ES2751022T3 (es) | 2007-07-09 | 2020-03-30 | Genentech Inc | Prevención de la reducción de enlaces disulfuro durante la producción recombinante de polipéptidos |
DK2233149T3 (en) | 2007-10-16 | 2016-05-17 | Zymogenetics Inc | COMBINATION OF TRANSMEMBRANAKTIVATOR AND CALCIUM MODULATOR AND cyclophilin-LIGAND INTERAKTOR (TACI) AND ANTI-CD20 MEANS FOR TREATMENT OF AUTO-IMMUNE DISEASE |
US9026372B2 (en) | 2007-11-21 | 2015-05-05 | Accentia Biopharmaceuticals, Inc. | Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen |
UA104579C2 (uk) | 2007-12-10 | 2014-02-25 | Байокрист Фармасьютикалз, Инк. | Спосіб лікування раку кровотворної системи із застосуванням фородезину у комбінації з ритуксимабом |
EP2077281A1 (de) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
WO2009126944A1 (en) | 2008-04-11 | 2009-10-15 | Trubion Pharmaceuticals, Inc. | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
AR073295A1 (es) | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
CN102271683B (zh) * | 2008-11-13 | 2014-07-09 | 吉里德卡利斯托加公司 | 恶性血液病的治疗 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
LT2464725T (lt) | 2009-08-11 | 2020-06-10 | F. Hoffmann-La Roche Ag | Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
RU2573994C2 (ru) | 2010-02-10 | 2016-01-27 | Иммьюноджен, Инк | Антитела против cd20 и их применение |
WO2011134899A1 (en) * | 2010-04-27 | 2011-11-03 | Roche Glycart Ag | Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor |
BR112013002535A2 (pt) * | 2010-08-03 | 2019-09-24 | Hoffmann La Roche | biomarcadores de leucemia linfocítica crônica (cll) |
WO2012019168A2 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
RU2013156435A (ru) | 2011-07-06 | 2015-08-20 | МорфоСис АГ | Терапевтические комбинации анти-cd20 и анти-gm-csf антител и их применения |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (de) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
EP2833892A4 (de) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | Modifizierte polynukleotide zur herstellung von in der onkologie nützlichen proteinen und peptiden |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
TW201427667A (zh) * | 2012-11-20 | 2014-07-16 | Celgene Avilomics Res Inc | 治療和布魯頓(bruton’s)酪胺酸激酶相關之疾病或失調的方法 |
TW201427668A (zh) * | 2012-11-20 | 2014-07-16 | Celgene Avilomics Res Inc | 治療和布魯頓(bruton’s)酪胺酸激酶相關之疾病或失調的方法 |
EP2922826A4 (de) * | 2012-11-20 | 2016-08-03 | Celgene Avilomics Res Inc | Verfahren zur behandlung einer krankheit oder erkrankung im zusammenhang mit bruton-tyrosinkinase |
ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
AU2014329452B2 (en) | 2013-10-03 | 2019-06-20 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
CN103525823A (zh) * | 2013-10-14 | 2014-01-22 | 朱慧兰 | 一种用于治疗荨麻疹的cd20嵌合抗体的制备方法 |
PE20210107A1 (es) | 2013-12-17 | 2021-01-19 | Genentech Inc | Anticuerpos anti-cd3 y metodos de uso |
BR112017001860A2 (pt) | 2014-07-31 | 2018-02-27 | Uab Research Foundation | peptídeo sintético, composição farmacêutica, métodos, regime de dosagem, e, anticorpo monoclonal |
EP3179858B1 (de) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Formen und zusammensetzungen eines erk-inhibitors |
AU2015314744A1 (en) | 2014-09-12 | 2017-03-02 | Genentech, Inc. | Anti-CLL-1 antibodies and immunoconjugates |
US20180258143A1 (en) | 2015-05-30 | 2018-09-13 | Molecular Templates, Inc. | De-Immunized, Shiga Toxin A Subunit Scaffolds and Cell-Targeting Molecules Comprising the Same |
PE20180330A1 (es) | 2015-06-16 | 2018-02-13 | Genentech Inc | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso |
CN107847568B (zh) | 2015-06-16 | 2022-12-20 | 豪夫迈·罗氏有限公司 | 抗cll-1抗体和使用方法 |
CN113999312A (zh) | 2015-06-24 | 2022-02-01 | 豪夫迈·罗氏有限公司 | 具有定制亲和力的抗转铁蛋白受体抗体 |
JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Cd3結合ポリペプチド |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
AU2016333512B2 (en) | 2015-10-02 | 2022-11-17 | F. Hoffmann-La Roche Ag | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use |
CA3042435A1 (en) | 2016-11-15 | 2018-05-24 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
CN110087530A (zh) | 2016-12-07 | 2019-08-02 | 普罗根尼蒂公司 | 胃肠道检测方法、装置和*** |
GB201703876D0 (en) | 2017-03-10 | 2017-04-26 | Berlin-Chemie Ag | Pharmaceutical combinations |
EP3600416B1 (de) | 2017-03-30 | 2023-06-07 | Biora Therapeutics, Inc. | Behandlung einer erkrankung des gastrointestinaltraktes mit einem immunmodulatorischen mittel, das mit einer einnehmbaren vorrichtung freigesetzt wird. |
WO2018237168A1 (en) * | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | DOSING PARAMETERS FOR CD47 TARGETING THERAPIES WITH HEMATOLOGICAL MALIGNANCIES |
MA51793A (fr) | 2018-02-08 | 2020-12-16 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène et procédés d'utilisation |
US20230009902A1 (en) | 2018-06-20 | 2023-01-12 | Progenity, Inc. | Treatment of a disease or condition in a tissue orginating from the endoderm |
WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
EP3883635A1 (de) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Verfahren und vorrichtungen zur behandlung einer krankheit mit biotherapeutika |
EP3870261B1 (de) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Einnehmbare vorrichtung zur abgabe eines therapeutischen mittels an den magen-darm-trakt |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0173494A3 (de) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimäre Rezeptoren durch Verbindung und Expression von DNS |
EP0247091B1 (de) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
USRE38008E1 (en) | 1986-10-09 | 2003-02-25 | Neorx Corporation | Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof |
US6893625B1 (en) | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
CA1341235C (en) | 1987-07-24 | 2001-05-22 | Randy R. Robinson | Modular assembly of antibody genes, antibodies prepared thereby and use |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5691320A (en) | 1987-10-28 | 1997-11-25 | Pro-Neuron, Inc. | Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5439665A (en) | 1988-07-29 | 1995-08-08 | Immunomedics | Detection and treatment of infectious and inflammatory lesions |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5441871A (en) * | 1989-06-01 | 1995-08-15 | Health Research, Inc. | Monoclonal antibody reactive to human leukemia and lymphoma cells and methods of using same for diagnosis and treatment |
KR100191223B1 (ko) * | 1989-07-28 | 1999-06-15 | 둘락 노먼 씨. | 인터루킨-4의 정제방법 및 이를 함유하는 약제학적 조성물 |
US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
SE8903003D0 (sv) | 1989-09-12 | 1989-09-12 | Astra Ab | Novel medical use |
US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
JPH06501705A (ja) | 1990-11-05 | 1994-02-24 | ブリストル−マイアーズ スクイブ カンパニー | 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療 |
JP3105629B2 (ja) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
NZ243706A (en) | 1991-07-25 | 1994-08-26 | Idec Pharma Corp | Recombinant monkey antibodies, pharmaceutical compositions |
MX9204374A (es) | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
ZA93391B (en) * | 1992-01-21 | 1993-10-06 | Tamrock World Corp | Battery changer on a mobile machine |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
AU5361794A (en) | 1992-10-14 | 1994-05-09 | Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5691135A (en) | 1993-01-26 | 1997-11-25 | The Regents Of The University Of California | Immunoglobulin superantigen binding to gp 120 from HIV |
GB9304745D0 (en) * | 1993-03-09 | 1993-04-28 | Oncholab Ab | Use of pharmaceutical formulations |
US5801005A (en) | 1993-03-17 | 1998-09-01 | University Of Washington | Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
US5565491A (en) * | 1994-01-31 | 1996-10-15 | Bristol-Myers Squibb Company | Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation |
US5658590A (en) * | 1995-01-11 | 1997-08-19 | Eli Lilly And Company | Treatment of attention-deficit/hyperactivity disorder |
NZ305784A (en) * | 1995-04-12 | 2001-03-30 | Procter & Gamble | Benzimidazole containing medicaments for treating cancers, tumors and viral infections |
SK14298A3 (en) * | 1995-08-03 | 1998-09-09 | Procter & Gamble | Use of griseofulvin for inhibiting the growth of cancers |
MX9800998A (es) * | 1995-08-04 | 1998-04-30 | Procter & Gamble | Uso de fluconazol para inhibir el crecimiento de canceres. |
CA2271464A1 (en) * | 1996-11-15 | 1998-05-22 | Baxter International Inc. | Conditioning for allogeneic stem cell transplantation |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
IL141349A0 (en) * | 1998-08-11 | 2002-03-10 | Idec Pharma Corp | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 anti-body |
AU6047099A (en) * | 1998-09-24 | 2000-04-10 | Boston Medical Center Corporation | Compositions and methods for the treatment of chronic lymphocytic leukemia |
AU761516B2 (en) | 1998-11-09 | 2003-06-05 | Biogen Inc. | Chimeric anti-CD20 antibody treatment of patients receiving BMT or PBSC transplants |
EP1949910A1 (de) * | 1998-11-09 | 2008-07-30 | Biogen Idec, Inc. | Behandlung von CLL unter Verwendung chimärer Anti-CD20-Antikörper |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
EP1286692A4 (de) | 2000-04-25 | 2004-11-17 | Idec Pharma Corp | Intrathekale verabreichung von rituximab zur behandlung von lymphomen des zenralen nervensystems |
JP2004111746A (ja) | 2002-09-19 | 2004-04-08 | Fujitsu Ltd | 半導体装置及びその製造方法 |
NZ568769A (en) | 2002-10-17 | 2010-04-30 | Genmab As | Human monoclonal antibodies against CD20 |
AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
-
1999
- 1999-11-09 EP EP08006154A patent/EP1949910A1/de not_active Withdrawn
- 1999-11-09 ES ES05022104T patent/ES2351149T3/es not_active Expired - Lifetime
- 1999-11-09 AT AT05022104T patent/ATE479443T1/de active
- 1999-11-09 MX MXPA01004648A patent/MXPA01004648A/es active IP Right Grant
- 1999-11-09 CA CA2350058A patent/CA2350058C/en not_active Expired - Lifetime
- 1999-11-09 EP EP99960232A patent/EP1131093A4/de not_active Withdrawn
- 1999-11-09 JP JP2000580657A patent/JP4842435B2/ja not_active Expired - Lifetime
- 1999-11-09 CN CN2005100043686A patent/CN1679934B/zh not_active Expired - Lifetime
- 1999-11-09 KR KR1020017005716A patent/KR20010103655A/ko not_active Application Discontinuation
- 1999-11-09 US US09/436,347 patent/US7682612B1/en not_active Expired - Fee Related
- 1999-11-09 EP EP05022104A patent/EP1616572B1/de not_active Revoked
- 1999-11-09 BR BR9915164-2A patent/BR9915164A/pt not_active Application Discontinuation
- 1999-11-09 CN CNB998143294A patent/CN1191850C/zh not_active Expired - Lifetime
- 1999-11-09 DE DE69942727T patent/DE69942727D1/de not_active Expired - Lifetime
- 1999-11-09 KR KR1020117013133A patent/KR101092132B1/ko active IP Right Review Request
- 1999-11-09 AU AU17149/00A patent/AU761844C/en not_active Expired
- 1999-11-09 EP EP10010718A patent/EP2289543A1/de not_active Ceased
- 1999-11-09 DK DK05022104.3T patent/DK1616572T3/da active
- 1999-11-09 ES ES09002504.0T patent/ES2543819T3/es not_active Expired - Lifetime
- 1999-11-09 PT PT05022104T patent/PT1616572E/pt unknown
- 1999-11-09 DK DK09002504.0T patent/DK2055313T3/en active
- 1999-11-09 EP EP08006155A patent/EP1949911A3/de not_active Withdrawn
- 1999-11-09 WO PCT/US1999/026308 patent/WO2000027428A1/en active Search and Examination
- 1999-11-09 EP EP20090002504 patent/EP2055313B1/de not_active Revoked
- 1999-11-09 TR TR2001/01299T patent/TR200101299T2/xx unknown
- 1999-11-09 EP EP08006156A patent/EP1949912A3/de not_active Withdrawn
- 1999-11-09 PT PT90025040T patent/PT2055313E/pt unknown
-
2001
- 2001-05-08 ZA ZA200103720A patent/ZA200103720B/en unknown
-
2002
- 2002-11-29 HK HK02108630A patent/HK1047043A1/xx unknown
-
2009
- 2009-12-02 US US12/629,472 patent/US8206711B2/en not_active Expired - Fee Related
-
2010
- 2010-07-20 JP JP2010163041A patent/JP2010285439A/ja active Pending
- 2010-11-04 CY CY20101100994T patent/CY1111173T1/el unknown
-
2015
- 2015-07-20 CY CY20151100638T patent/CY1116510T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69942727D1 (de) | Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie | |
MY121548A (en) | Compounds and methods for the treatment of cancer | |
DK0969866T3 (da) | Immunterapi af B-cellelidelser ved hjælp af anti-CD22 antistoffer | |
MD1616G2 (ro) | Compuşi triciclici şi metodă de inhibare a receptorului tirozin kinazei pentru factorul de creştere epidermic, compoziţie farmaceutică, metode de prevenire a implantării blastocitului şi tratament al mamiferelor | |
GEP20012500B (en) | Inhibitors of Protein Farnesyl Transferase | |
DE3770305D1 (de) | Pumpenkoerper zum anschluss einer bestrahlungskammer an ein system zur behandlung eines patienten durch photoaktivierung. | |
DE69715000D1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
EE9700225A (et) | Meetod diabetes mellituse raviks, kasutades KKF | |
ATE198158T1 (de) | Verfahren zur behandlung geschädigter und verminderter zellen | |
ATE232394T1 (de) | Verwendung von modifiziertem c-reaktiven protein zur herstellung eines medikaments zur behandlung von krebs | |
DE3381467D1 (de) | Plasmaproteinkonzentrate mit reduzierter thrombogenizitaet und deren verwendung in klinischer ersatztherapie. | |
WO2004007676A3 (en) | Combination therapy for the treatment of neoplasms | |
DE69815840D1 (de) | Verwendung von tall-104 zellen in kombination mit adriamyzin oder cisplatin zur behandlung von malignen tumoren | |
DE59002772D1 (de) | Verwendung von Dextransulfat, gegebenenfalls in Kombination mit anti-androgenen Mitteln zur Behandlung des humanen Protatakarzinoms. | |
ZA849576B (en) | 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases | |
DE69129693D1 (de) | Verwendung von nickel und bromide ionen für die behandlung von psoriasis | |
MXPA04005207A (es) | Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos. | |
ATE108331T1 (de) | Verwendung von tnf zur herstellung eines arzneimittels zur behandlung von psoriasis. | |
DE69111457D1 (de) | Katheter und vorrichtung zur behandlung, insbesondere von lungenembolien. | |
DE69006633D1 (de) | Verwendung von Gestoden zur Herstellung von Arzneimitteln. | |
EA199800822A1 (ru) | Способ лечения избыточной агрессии | |
EP0139005A4 (de) | Antitumor-zusammensetzung, verfahren zum behandeln von tumoren und verwendung der zusammensetzung zum behandeln von tumoren. | |
TH104658A3 (th) | การรักษาโรคเนื้อร้ายทางโลหิตวิทยาที่เกี่ยวข้องกับเซลเนื้องอกที่ไหลเวียนโดยใช้แอนติบอดีแอนติ-cd 20 ชนิดไคเมอริค | |
ATE102832T1 (de) | Regionale chemotherapie mit 4hydroperoxycyclophosphamid. |